Eli Lilly agreed to buy 4E Therapeutics, a private, Austin-based non-opioid pain drug developer, adding early-stage pipeline assets focused on MNK inhibition. 4E’s lead program, 4ET1103, is in development for nerve-damage-related pain and has completed an early human safety study; the company also has programs in migraines and acute pain. Lilly did not disclose financial terms. The purchase extends a rapid string of pain-focused dealmaking this year that includes Lilly’s earlier acquisition of SiteOne Therapeutics, underscoring how aggressively large pharma is trying to build an opioid-free chronic pain franchise. For investors and trial operators, the deal also highlights how MNK-eIF4E pathway modulation is being positioned as a differentiation strategy in peripheral sensory neurons—while aiming to avoid central nervous system effects associated with addiction risk and cognitive impairment.